Cargando…

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soysal, Ahmet, Gönüllü, Erdem, Karabayır, Nalan, Alan, Servet, Atıcı, Serkan, Yıldız, İsmail, Engin, Havva, Çivilibal, Mahmut, Karaböcüoğlu, Metin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330011/ https://www.ncbi.nlm.nih.gov/pubmed/34324409 http://dx.doi.org/10.1080/21645515.2021.1953344

Ejemplares similares

Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy
por: Soysal, Ahmet, et al.
Publicado: (2021)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
por: Atıcı, Serkan, et al.
Publicado: (2023)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
por: Jiang, Zhujun, et al.
Publicado: (2022)

Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival
por: Sevinc, Sultan Acar, et al.
Publicado: (2022)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
por: Zhang, Lu, et al.
Publicado: (2022)

Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine
por: Unver, Suat, et al.
Publicado: (2021)

Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine
por: Oshiro, Telma Miyuki, et al.
Publicado: (2022)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
por: Fernandes, Eder Gatti, et al.
Publicado: (2021)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022)

CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk
por: Calil, Valdenise Martins Laurindo Tuma, et al.
Publicado: (2021)

Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease
por: Gao, Xing-Su, et al.
Publicado: (2022)

Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2022)

Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions
por: Li, Chunmei, et al.
Publicado: (2022)

Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
por: Jo, Juandy, et al.
Publicado: (2022)

Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination
por: da Silva, Almir Ribeiro, et al.
Publicado: (2022)

COVID-19 Pneumonia After SARS-CoV-2 Vaccination with CoronaVac: A Case Series from Turkey
por: Meriç Çoban, Mehmet, et al.
Publicado: (2022)

Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile
por: Jara, Alejandro, et al.
Publicado: (2022)

Waning anti-SARS-CoV-2 receptor-binding domain total antibody in CoronaVac-vaccinated individuals in Indonesia
por: Harapan, Harapan, et al.
Publicado: (2023)

Neutralization of Wild-Type and Alpha SARS-CoV-2 Variant by CoronaVac® Vaccine and Natural Infection- Induced Antibodies
por: Özkaya, Esra, et al.
Publicado: (2023)

Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil
por: Estofolete, Cassia F., et al.
Publicado: (2021)

Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers
por: Demirbakan, H., et al.
Publicado: (2022)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
por: Vargas, Leonardo, et al.
Publicado: (2022)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
por: Fonseca, Marcela Helena Gambim, et al.
Publicado: (2022)

Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination
por: Li, Jianhua, et al.
Publicado: (2022)

SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers
por: Santi, Theresia, et al.
Publicado: (2022)

Early effects of inactivated (CoronaVac) SARS-CoV-2 vaccine on retrobulbar vascular blood flow and retinal vascular density
por: Yorgun, Mücella Arıkan, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
por: Türkoğlu, Recai, et al.
Publicado: (2022)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

Factors Associated with Vaccine Breakthrough Incidence among Health Care Workers Vaccinated with Inactivated SARS-CoV-2 Vaccine (CoronaVac)
por: Anshory, Muhammad, et al.
Publicado: (2022)

Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine
por: Wang, Chan, et al.
Publicado: (2022)

An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection
por: Scher, Ann I, et al.
Publicado: (2022)

The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells
por: Bilgin, Huseyin, et al.
Publicado: (2022)

Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
por: Chua, Jia Xin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bagomf6v3m384a9qv4m17r8c6d